Drugs News and Research

RSS

Formatech issued patent covering novel formulation methods to enhance solubility of certain hydrophobic compounds

Today, Formatech, Inc. announced the issuance of U.S. patent 7,659,310, entitled “Methods of Enhancing Solubility of Agents” which covers novel formulation methods to enhance the solubility of certain hydrophobic compounds.

12 Feb 2010

Also in Global Health News: China's health care system; Breastfeeding practices in Pakistan; HIV transmission in MSM; Abu Dhabi joins malaria fight

The Los Angeles Times examines China's transition to "Western-style privatized medicine" through the government's "$124-billion overhaul, chiefly to improve service in rural areas." The article details the efforts of a woman from Inner Mongolia to get care in Beijing for her ailing father and looks at climbing health care costs and the growing "black market for medical care" (Pierson, 2/11).

12 Feb 2010

Regence introduces Evolve to meet full spectrum of consumers' healthcare needs

Regence introduces Evolve, a new portfolio of individual health plans designed to meet the full spectrum of consumers' needs. From children needing preventative care, unemployed individuals seeking core coverage or a family searching for comprehensive benefits, Evolve has options to meet each unique situation.

12 Feb 2010

Proving value a challenge for comparative effectiveness and pharmaceutical technologies

The Wall Street Journal reports that "an examination of one of the best-known examples of a comparative-effectiveness analysis shows how complicated such a seemingly straightforward idea can get" as officials look for savings in the health care system." One study, called Courage, "found that the most common heart surgery -- a $15,000 procedure that unclogs arteries using a small scaffold or stent -- usually yields no additional benefit when used with a cocktail of generic drugs in patients suffering from chronic chest pain."

12 Feb 2010

AMC receives GWTG-Stroke Gold Performance Achievement Award for caring stroke patients

Adventist Medical Center recently received the American Heart Association/American Stroke Association's Get With The Guidelines (GWTG) - Stroke Gold Performance Achievement Award. The award recognizes AMC's commitment and success in implementing a higher standard of stroke care by ensuring that stroke patients receive treatment according to nationally accepted standards and recommendations provided by the AHA/ASA.

12 Feb 2010

Sales of Cobroxin exceeds XenaCare Holdings' projections for first 45 days of 2010

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, announced today that it has begun distributing and selling Cobroxin through mass food and drug retail chains in the Northeast, Southeast, Middle Atlantic and Midwest regions.

12 Feb 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

Researchers identify potential drug candidate that halts tumor growth

A novel - and rapid - anti-cancer drug development strategy has resulted in a new drug that stops kidney and pancreatic tumors from growing in mice. Researchers at the Moores Cancer Center at the University of California, San Diego, have found a drug that binds to a molecular "switch" found in cancer cells and cancer-associated blood vessels to keep it in the "off" position.

12 Feb 2010

Blood test to detect elevated levels of antibodies unique to Alzheimer’s disease developed

OPKO Health, Inc. today announced the development of a simple diagnostic blood test for Alzheimer’s disease. The test, designed to detect elevated levels of antibodies unique to Alzheimer’s disease, was approximately 95% accurate in initial testing.

12 Feb 2010

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.

12 Feb 2010

British rhubarb could be a potential source of anti-cancer agent

Eating rhubarb baked in a crumble is not only tasty it may also be the best way to take advantage of its health benefits, and could lead to the development of new cancer treatments.

From Sheffield Hallam University 11 Feb 2010

Cognitive behavioral therapy effective for insomnia and chronic pain

Cognitive behavioral therapy for insomnia significantly improved sleep for patients with chronic neck or back pain and also reduced the extent to which pain interfered with their daily functioning, according to a study by University of Rochester Medical Center researchers.

11 Feb 2010

RadPharm and Medifacts International announce merger

RadPharm Inc., a leading Imaging Core Laboratory, and Medifacts International, Inc., a leading Cardiovascular Core Laboratory, today announced the merger of their business operations. The combined company will be named CoreLab Partners ("CoreLabs") and will have its corporate headquarters in Princeton, New Jersey.

11 Feb 2010

LabCorp reports financial results for quarter and year ended December 31, 2009

Laboratory Corporation of America® Holdings (LabCorp®) today announced results for the quarter and year ended December 31, 2009.

11 Feb 2010

SafeBridge Consultants validates improved hygiene air sampling and analytical method for naproxen sodium

SafeBridge® Consultants, Inc. headquartered in Mountain View, California announced today that its industrial hygiene analytical laboratory has recently validated an industrial hygiene air sampling and analytical method with improved analytical sensitivity for measurement of naproxen sodium on filters. SafeBridge now has a validated method that will detect as low as 20 picograms per filter in an air sample collected on appropriate media. This limit of detection is four (4) to five (5) times lower than methods available from other commercial laboratories.

11 Feb 2010

PROMETA Treatment Program rapidly reduces cravings for methamphetamine subjects: Study

Hythiam, Inc. announced today that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA® Treatment Program on methamphetamine dependent subjects were published in the Journal of Psychopharmacology, a peer-reviewed, international journal that publishes original research and review articles on preclinical and clinical aspects of psychopharmacology.

11 Feb 2010

New genetic 'hotspots' may help doctors devise therapies for bowel cancer patients

Cancer Research UK scientists have identified the frequency of new genetic 'hotspots' which could help doctors to tailor therapies to as many as 3,000 additional bowel cancer patients each year, according to research published in the British Journal of Cancer today.

11 Feb 2010

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

4SC AG a drug discovery and development company focused on autoimmune and cancer indications, today announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas.

11 Feb 2010

Simcere Pharmaceutical Group subsidiary receives Chinese SFDA approval for Zanamivir

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that one of its subsidiaries, Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd., has received new drug registration approval from the State Food and Drug Administration ("SFDA") to manufacture and sell Zanamivir, a neuraminidase inhibitor inhalant used in the prevention and treatment of Influenza A and Influenza B. Zanamivir is marketed globally by GlaxoSmithKline under the trade name Relenza.

11 Feb 2010

Role of evidence-based pathways in providing high quality, cost effective oncology care

Although health care reform is taking a back seat to the economy on Capitol Hill, discussions continue in the health care industry on how best to lower the cost of care while maintaining or improving patient outcomes.

11 Feb 2010

Drugs News and Research

Formatech issued patent covering novel formulation methods to enhance solubility of certain hydrophobic compounds

Also in Global Health News: China's health care system; Breastfeeding practices in Pakistan; HIV transmission in MSM; Abu Dhabi joins malaria fight

Regence introduces Evolve to meet full spectrum of consumers' healthcare needs

Proving value a challenge for comparative effectiveness and pharmaceutical technologies

AMC receives GWTG-Stroke Gold Performance Achievement Award for caring stroke patients

Sales of Cobroxin exceeds XenaCare Holdings' projections for first 45 days of 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Researchers identify potential drug candidate that halts tumor growth

Blood test to detect elevated levels of antibodies unique to Alzheimer’s disease developed

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

British rhubarb could be a potential source of anti-cancer agent

Cognitive behavioral therapy effective for insomnia and chronic pain

RadPharm and Medifacts International announce merger

LabCorp reports financial results for quarter and year ended December 31, 2009

SafeBridge Consultants validates improved hygiene air sampling and analytical method for naproxen sodium

PROMETA Treatment Program rapidly reduces cravings for methamphetamine subjects: Study

New genetic 'hotspots' may help doctors devise therapies for bowel cancer patients

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

Simcere Pharmaceutical Group subsidiary receives Chinese SFDA approval for Zanamivir

Role of evidence-based pathways in providing high quality, cost effective oncology care

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News